Literature DB >> 28570785

Dual-Action Cancer Therapy with Targeted Porous Silicon Nanovectors.

Anna Cifuentes-Rius1, Angela Ivask1, Ester Sporleder1, Ishdeep Kaur1, Yasmin Assan1, Shasha Rao2, David Warther3, Clive A Prestidge2, Jean-Olivier Durand3, Nicolas H Voelcker1.   

Abstract

There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody-functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two-stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer; cytotoxicity; drug delivery; nanoparticles

Mesh:

Substances:

Year:  2017        PMID: 28570785     DOI: 10.1002/smll.201701201

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  2 in total

1.  Porous Silicon Nanoparticles Embedded in Poly(lactic-co-glycolic acid) Nanofiber Scaffolds Deliver Neurotrophic Payloads to Enhance Neuronal Growth.

Authors:  Jonathan M Zuidema; Courtney M Dumont; Joanna Wang; Wyndham M Batchelor; Yi-Sheng Lu; Jinyoung Kang; Alessandro Bertucci; Noel M Ziebarth; Lonnie D Shea; Michael J Sailor
Journal:  Adv Funct Mater       Date:  2020-05-11       Impact factor: 18.808

Review 2.  Recent Developments in Porous Silicon Nanovectors with Various Imaging Modalities in the Framework of Theranostics.

Authors:  Jing Qian; Huang Wen; Konstantin Tamarov; Wujun Xu; Vesa-Pekka Lehto
Journal:  ChemMedChem       Date:  2022-03-18       Impact factor: 3.540

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.